We investigated the relationships between L/S promoter (SERTPR) and l/s intron2 (SERTin2) genetic variants of serotonin transporter (SERT) polymorphisms with olanzapine-induced weight gain and treatment response in 94 female schizophrenic patients treated with olanzapine for up to 3 months. Body mass index (BMI) was calculated for each patient prior to olanzapine administration and 3 months afterwards. To assess and evaluate improvement of clinical psychotic symptoms and therapeutic response to the antipsychotic, all patients were rated using the Positive and Negative Syndrome ScaLe (PANSS). Overall, the presence of S SERTPR allelic variant and SS genotype was associated with significantly higher weight gain in subjects who were non-obese at the time of admission. The presence of L SERTPR variant was associated with significantly better treatment response measured with total PANSS and general PANSS subscale, while the presence of l SERTin2 variant determined better treatment response only in several items. No evidence of linkage disequilibrium between the two loci was found in the sample. These findings identify genetic factors associated with oLanzapine-induced weight gain and treatment response in femaLe schizophrenic patients.
Allison D.B. and Casey D.E. (2001) Antipsychotic weight gain: a review of the literature . J Clin Psychiatry62: 22—31
2.
Bagnall A.M. , Jones L. , Ginnelly L. , Lewis R. , Glanville J. , Gilbody S. , Davies L. , Torgerson D. , Kleijnen J. (2003) A systematic review of antipsychotic drugs in schizophrenia . Health Techno Assess7(13): 1—193
3.
Benton D. (2004) Role of parents in the determination of the food preferences of children and the development of obesity . Int J Obes Relat Metab Disord28: 858—869
4.
Cohen D. (2004) Atypical antipsychotics and new onset of diabetes mellitus . Pharmacopsychiatry37: 1—11
5.
Collier D.A. , Stober G. , Li T. , Heils A. , Catalano M. , Di Bella D. , Arranz M.J. , Murray R.M. , Vallada H.P. , Bengel D. , Muller C.R. , Roberts G.W. , Smeraldi E. , Kirov G. , Sham P. , Lesch K.P. (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders . Mol Psychiatry1: 453—460
6.
Coyle N. , Jones I. , Robertson E. , Lendon C. , Craddock N. (2000) Variation at the serotonin transporter gene influences susceptibility to bipolar affective puerperal psychosis . Lancet356: 1490—1491
7.
Dubertret C. , Hanoun N. , Adès J. , Hamon M. , Gorwood P. (2005) Family-based association study of the 5-HT transporter gene and schizophrenia . International Journal of Neuropsychopharmacology8: 87—92
8.
Excoffier L. , Laval G. , Schneider S. (2006) Arlequin ver. 3.01: An Integrated Software Package for Population Genetic Data Analysis. University of Bern , Switzerland
9.
Fan J.B. , Sklar P. (2005) Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia . Mol Psychiatry10: 928—938
10.
Fuller R.W. (1994) Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis . Life Sci55: 163—167
11.
Gelenrter J. , Cubells J.F. , Kidd J.R. , Pakstis A.J. , Kidd K.K. (1999) Population studies of polymorphisms of the serotonin transporter protein gene . Am J Med Genet88: 61—66
12.
Golimbet V.E. , Alfimova M.V. , Shchebatykh T.V. , Abramova L.I. , Kaleda V.G. , Rogaev E.I. (2004) Serotonin transporter polymorphism and depressive-related symptoms in schizophrenia. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 126: 1—7
13.
Graham K A. , Perkins D O. , Edwards L J. , Barrier R.C. Jr , Lieberman J A. , Harp J B. (2005) Effects of olanzapine on body composition and energy expenditure in adults with first-episode psyhosis . Am J Psychiatry162: 118—123
14.
Guo S.W. , Thompson E.A. (1992) Performing the exact test of Hardy-Weinberg proportions for multiple alleles . Biometrics48: 361—372
15.
Haddad P. (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. Journal ofPsychopharmacology19: 16—27
16.
Hanna G.L. , Himle J A. , Curtis G C. , Koram D Q. , Veenstra-VanderWeele J. , Leventhal B L. , Cook E.H. Jr (1998) Serotonin transporter and serotonin transporter promoter affects onset of paroxetine treatment seasonal variation in blood serotonin in families with obsessive—compulsive disorder . Neuropsychopharmacology18: 102—111
17.
Heils A. , Teufel A. , Petri S. , Stober G. , Riederer P. , Bengel D. , Lesch K.P. (1996) Allelic variation of human serotonin transporter gene expression . J Neurochem66: 2621—2624
18.
Herken H. , Erdal M.E. , Aynacioglu A.S. , Barlas O. , Cataloluk O. , Esgi K. , Brockmoller J. , Kaiser R. (2002) Frequency of the 17-bp variable number of tandem repeat polymorphism in Turkish schizophrenic patients . Schizophr Res58: 99—100
19.
Holm S. ( 1979) A simple sequentially rejective multiple test procedure . Scand J Stat6: 65—70
20.
Hong C.J. , Lin C.H. , Yu Y.W. , Yang K.H. , Tsai S.J. (2001) Genetic variant of the serotonin system and weight change during clozapine treatment . Pharmacogenetics11: 265—268
21.
Hranilovic D. , Stefulj J. , Furac I. , Kubat M. , Balija M. , Jernej B. (2003) Serotonin transporter gene promoter (5-HTTLPR) and intron 2 (VNTR) polymorphisms in croatian suicide victims . Biol Psychiatry54: 884—889
22.
Ito K. , Yoshida K. , Sato K. , Takahashi H. , Kamata M. , Higuchi H. , Shimizu T. , Itoh K. , Inoue K. , Tezuka T. , Suzuki T. , Ohkubo T. , Sugawara K. , Otani K. (2002) A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine . Psychiatry Res111: 235—239
23.
Jacobs B.L. , Fornal C.A. (1995) Serotonin and behaviour: a general hypothesis. In Bloom F E , Kupfer D J (eds), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York
24.
Koch S. , Perry K.W. , Bymaster F.P. (2004) Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat . Neuropharmacology46: 232—242
25.
Kunugi H. , Hattori M. , Kato T. , Tatsumi M. , Sakai T. , Sasaki T. , Hirose T. , Nanko S. (1997) Serotonin trasporter gene polymorphism: ethnic difference and possible associations with bipolar affective disorder . Mol Psychiatry2: 457—462
26.
Lee I M. , Paffenbarger R.S. Jr (1992) Changes in body weight and longevity . JAMA268: 2045—2049
27.
Lesch K.P. (2001) Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs . European Neuropsychopharmacology11: 457—474
28.
Lesch K.P. , Balling U. , Gross J. , Strauss K. , Wolozin B.L. , Murphy D.L. , Riederer P. (1994) Organization of the human serotonin transporter gene . J Neural Transm Gen Sect95: 157—162
29.
Lesch K.P. , Bengel D. , Heils A. , Sabol S.Z. , Greenberg B.D. , Petri S. , Benjamin J. , Muller C.R. , Hammer D.H. , Murphy D.L. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region , Science274: 1527—1531
30.
MacKenzie A. , Quinn J. (1999) A serotonin transporter gene intone 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo . Proc Natl Acad Sci USA96: 15251—15255
31.
Magni P. , Liuzzi A. , Ruscica M. , Dozio E. , Ferrerio S. , Bussi I. , Minocci A. , Castagna A. , Motta M. , Savia G. (2005) Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference . Clin Endocrinol (Oxf)62: 189—196
32.
Masand P.S. , Gupta S. (1999) Selective serotonine-reputake inhibitors: an update . Harv Rev Psychiatry7: 69—84
33.
Mendes de Oliveira J R. , Otto P A. , Vallada H. , Lauriano V. , Elkis H. , lafer B. , Vasquez L. , Gentil V. , Passos-Bueno M R. , Zatz M. ( 1998) Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brasilian patients affected by bipolar disorders and schizophrenia . Am J Med Genet81: 225—227
34.
Miller S.A. , Dykes D.D. , Polesky H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cell . Nucl Acid Res16: 1215
35.
Müller D.J. , Muglia P. , Fortune T. , Kennedy J.L. (2004) Pharmacogenetics of antipsychotic-induced weight gain . Pharmacological Research49: 309—329
36.
National Institutes of Health Consensus Development Panel on the Health Implications of Obesity (1985) Health implications of obesity . Ann Intern Med103: 1073—1077
37.
Ramamoorthy S. , Giovanetti E. , Qian Y, Blakely (1998). Phosphorylation and regulation of antidepressant-sensitive serotonin transporters . J Biol Chem273: 2458—2466
38.
Rausch J.L. , Johnson M.E. , Fei Y.J. , Li J.Q. , Shendarkar N. , Hobby H.M. , Ganapathy V. , Leibach F.H. (2002) Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI trial outcome . Biol Psychiatry51: 723—732
39.
Reynolds G.P. , Zhang Z.J. , Zhang X.B. (2002) Association of antipsychotic weigt gain with a 5-HT2C polymorphism . Lancet359: 2086—2087
Routh V.H. , Stern J.S. , Horwitz B.A. (1994) Serotonergic activity is depressed in the ventromedial hypothalamic nucleus of 12-day-old obese Zucker rats . American Journal of Physiology267: R712—R719
42.
Serretti A. , Lilli R. , Smeraldi E. (2002) Pharmacogenetics in affective disorders. EuropeanJournal of Pharmacology438: 117—128
43.
Slatkin M. , Excoffier L. (1996) Testing for linkage disequilibrium in genotypic data using the EM algorithm . Heredity76: 377—383
44.
Smeraldi E. , Benedetti F. , Zanardi R. (2002) Serotonin transporter promoter genotype and illness recurrence in mood disorders . European Neuropsychopharmacology12: 73—75
45.
Søeby K. , Larsen S.A. , Olsen L. , Rasmussen H.B. , Werge T. (2005) Serotonin transporter: evolution and impact of polymorphic transcriptional regulation. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 136B: 53—57
46.
Stober G. , Jatzke S. , Heils A. , Jungkunz G. , Fuchs E. , Knapp M. , Riederer P. , Lesch K.P. (1998) Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene . Eur Arch Psychiatry Clin Neurosci248: 82—86
47.
Tandon R. , Jibson M.D. (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia . Psychoneuroendocrinology28: 9—26
48.
Tecott L.H. , Sun L.M. , Akana S.F. , Strack A.M. , Lowenstein D.H. , Dallman M.F. , Julius D. (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonine receptors . Nature374: 542—546
49.
Templeman L.A. , Reynolds G.P. , Arranz B. , San L. ( 2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics andGenomics15: 195—200
50.
Tsai S.J. , Hong C.J. , Yu Y.W. , Lin C.H. , Song H.L. , Lai H.C. , Yang K.H. (2000) Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response . Schizophr Res44: 177—181
